Literature DB >> 18842530

Pancreatic cancer: a review and update.

Elizabeth Prechtel Dunphy1.   

Abstract

Pancreatic cancer will account for about 6% of all cancer-related deaths in 2008. Patients often present with advanced disease, so treatment remains a challenge. This article will review the risk factors, pathology features, clinical symptoms, diagnosis and staging guidelines, treatment, and nursing implications of pancreatic cancer. This article also will review studies that have precipitated the shift in systemic treatment from 5-fluorouracil to gemcitabine. Targeted therapies will further shift treatment strategies to improve survival as more is learned about the molecular basis of pancreatic cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18842530     DOI: 10.1188/08.CJON.735-741

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  5 in total

1.  Identification of pancreatic cancer-specific cell-surface markers for development of targeting ligands.

Authors:  David L Morse; Galen Hostetter; Yoganand Balagurunathan; Robert J Gillies; Haiyong Han
Journal:  Methods Mol Biol       Date:  2010

2.  Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

Authors:  Yang Chen; Yiqi DU; Ping Li; Fei Wu; Yan Fu; Zhaoshen Li; Yongzhang Luo
Journal:  Mol Clin Oncol       Date:  2014-03-27

3.  Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.

Authors:  Moitza Principe; Patrizia Ceruti; Neng-Yao Shih; Michelle S Chattaragada; Simona Rolla; Laura Conti; Marco Bestagno; Lorena Zentilin; Sheng-Hui Yang; Paola Migliorini; Paola Cappello; Oscar Burrone; Francesco Novelli
Journal:  Oncotarget       Date:  2015-05-10

Review 4.  Common pancreatic disease.

Authors:  Po Sing Leung
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  Clinical significance of clusterin expression in pancreatic adenocarcinoma.

Authors:  Junshuo Jin; Joon-Mee Kim; Yoon-Seok Hur; Won Pyo Cho; Keon-Young Lee; Seung-Ik Ahn; Kee Chun Hong; In-Sun Park
Journal:  World J Surg Oncol       Date:  2012-07-16       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.